SLC6A2
Sodium-dependent noradrenaline transporter
Protein Summary
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals. This gene encodes a member of the sodium:neurotransmitter symporter family. This member is a multi-pass membrane protein, which is responsible for reuptake of norepinephrine into presynaptic nerve terminals and is a regulator of norepinephrine homeostasis. Mutations in this gene cause orthostatic intolerance, a syndrome characterized by lightheadedness, fatigue, altered mentation and syncope. Alternatively spliced transcript variants encoding different isoforms have been identified in this gene.[provided by RefSeq, Feb 2010]
- ENST00000219833
- ENSP00000219833
- ENSG00000103546
- ENST00000379906
- ENSP00000369237
- ENST00000567238
- ENSP00000457375
- ENST00000568943
- ENSP00000457473
- NAT1
- NET1
- SLC6A5
- NET
- NAT1
- NET1
- SLC6A5
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
drug | 1 | ||
co-expressed gene | 0.99 | ||
ligand (chemical) | 0.9 | ||
molecular function | 0.9 | ||
microRNA | 0.73 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 1018.93 (req: < 5)
Gene RIFs: 157 (req: <= 3)
Antibodies: 129 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 1018.93 (req: >= 5)
Gene RIFs: 157 (req: > 3)
Antibodies: 129 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 14
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 2286
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drugs: 65